Loading
Q32 Bio Inc. Stock: price and insider trades · United States
US·Mcap US$231.3M
Q32 Bio Inc.: what insiders have been doing
Every trade that managers of Q32 Bio Inc. disclose to SEC (Form 4) is tracked on this page. Between 18 October 2025 and 18 October 2026, 3 insiders published 17 filings.
All open-market trades in the period are sales: 11 sales worth €434k, by 3 insiders, with no purchase on record. At €140k, the sale published on 27 August 2026 by Morrison Jodie Pope is the largest of the period (0.061% of market cap).
Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 17 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed no purchases and 26 sales.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
57
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€577,476
26 ops. · all time
Who traded when
BuySaleJodie Pope Morrison5 sales
Lee Kalowski5 sales
Shelia M. Violette4 sales
Analyst consensus: bullish or bearish?
Analysts rate Q32 Bio Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$39.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,027 of 24,148 companies
75.3
score / 100
Value59
Quality92
FCF yld-15%
Earn yld13%
EV/EBITDA7.9x
ROE72%
Gross mgn·
Net mgn55%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.77
Analyst consensus
6 analystsStrong buy
US$29.00Target US$39.67(+411%)US$59.00
Income statement
RevenueUS$53.7M
EBITDAUS$31.3M58% margin
Net incomeUS$29.8M62.9% margin
Valuation
PER (trailing)2.5x
PER (forward)-14.6x
P/Book1.7x
Beta-0.11
Balance sheet & cash
Market capUS$231.3M
Total debtUS$15.3M
Free Cash Flow-US$33.5M
Debt / Equity5%
Profitability & ownership
ROE72.1%
ROA14.7%
% insiders2.1%
% institutions87.7%
Last declaration on 14 October 2026
Declarations57 total
3,221 shares@ US$8.31980.011% mcap8.4% of flowCommon StockSEC:0001193125-26-421836:0
917 shares@ US$8.31970.0032% mcap6.0% of flowCommon StockSEC:0001193125-26-421835:0
1,301 shares@ US$8.31980.0045% mcap8.4% of flowCommon StockSEC:0001193125-26-421834:0
3,972 shares@ US$16.560.025% mcap53.5% of flowCommon StockSEC:0001193125-26-371293:0
9,845 shares@ US$16.560.061% mcap53.5% of flowCommon StockSEC:0001193125-26-371292:0
2,798 shares@ US$16.560.017% mcap37.5% of flowCommon StockSEC:0001193125-26-371291:0
132,000 shares0Common StockSEC:0001193125-26-309327:0
37,500 shares0Common StockSEC:0001193125-26-309331:0
53,250 shares0Common StockSEC:0001193125-26-309324:0
53,250 shares0Common StockSEC:0001193125-26-118052:0
37,500 shares0Common StockSEC:0001193125-26-118054:0
132,000 shares0Common StockSEC:0001193125-26-118053:0
3,995 shares@ US$4.514414.5% of flowCommon StockSEC:0001193125-26-083588:0
9,896 shares@ US$4.514414.5% of flowCommon StockSEC:0001193125-26-083585:0
2,815 shares@ US$4.514410.2% of flowCommon StockSEC:0001193125-26-083584:0
22,506 shares@ US$3.4625.7% of flowCommon StockSEC:0001193125-25-308328:0
9,072 shares@ US$3.460725.7% of flowCommon StockSEC:0001193125-25-308327:0
10,494 shares@ US$1.8016.2% of flowCommon StockSEC:0001193125-25-191452:0
2,990 shares@ US$1.8014.4% of flowCommon StockSEC:0001193125-25-191447:0
4,240 shares@ US$1.8016.2% of flowCommon StockSEC:0001193125-25-191442:0
53,250 shares0Common StockSEC:0000950170-25-028269:0
37,500 shares0Common StockSEC:0000950170-25-028245:0
37,500 shares0Common StockSEC:0000950170-25-028252:0
132,000 shares0Common StockSEC:0000950170-25-028261:0
4,574 shares@ US$3.1212.3% of flowCommon StockSEC:0000950170-24-115146:0
25 of 57 declarations
About Q32 Bio Inc.
Q32 Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. It is listed on NASDAQ under the ticker Q32.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
